Lapolla A, Fedele D, Aronica R, Garbeglio M, D'Alpaos M, Seraglia R, Traldi P
Istituto di Medicina Interna, Malattie del Metabolismo, Padova, Italy.
Rapid Commun Mass Spectrom. 1997;11(12):1342-6. doi: 10.1002/(SICI)1097-0231(199708)11:12<1342::AID-RCM972>3.0.CO;2-T.
Matrix-assisted laser desorption/ionization (MALDI) mass spectrometry has been employed for the evaluation of the glycation level of IgG from healthy subjects and also from well- and badly-controlled diabetic patients. The measurements have been performed on untreated plasma protein fractions. The data obtained have shown that a clear mass increase, originating from non-enzymatic glycation processes, is observed in the case of diabetic patients: for well-controlled ones it is in the range 512-1565 Da, while it becomes 827-4270 Da for badly-controlled diabetic patients. This approach indicates that MALDI mass spectrometry is a highly specific tool that can be employed in the metabolic control of diabetic patients and in studies relating the IgG glycation level to possible immunological impairment.
基质辅助激光解吸/电离(MALDI)质谱已被用于评估健康受试者以及血糖控制良好和控制不佳的糖尿病患者体内IgG的糖化水平。测量是在未经处理的血浆蛋白组分上进行的。获得的数据表明,在糖尿病患者中观察到了源自非酶糖化过程的明显质量增加:血糖控制良好的患者增加范围为512 - 1565道尔顿,而血糖控制不佳的糖尿病患者则为827 - 4270道尔顿。这种方法表明,MALDI质谱是一种高度特异性的工具,可用于糖尿病患者的代谢控制以及将IgG糖化水平与可能的免疫损伤相关联的研究。